Supplementary tables: Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer.docx

Supplementary table 1a: Versions of genomic sequencing and genes included (FoundationOne Version 1) Supplementary table 1b: Versions of genomic sequencing and genes included (FoundationOne Version 2) Supplementary table 1c: FoundationOne CDx (Version 3) Supplemental table 2: Detailed patient selection criteria Supplemental table 3: Patients with an unknown or indeterminate HER2 test results who met all other study inclusion criteria Supplemental table 4: First line anti-HER2 therapy regimens in HER2+ patients stratified by ERBB2 amplification status Supplemental table 5: Demographics and clinical characteristics of patients with HER2+ tumors who received first-line trastuzumab therapy Supplemental table 6: Concurrent genomic alterations Supplemental table 7: Distribution of ISH results for patients classified by IHC status (with positive ISH confirmation) (n = 59), by ERBB2 Amp Supplemental table 8: Adjusted clinical outcomes for 1L trastuzumab in patients whose tumors were clinically HER2+, adjusting for IHC status (n=142) Supplemental table 9: Adjusted clinical outcomes for 1L trastuzumab in patients by adjusting for KRAS status (n=142)